
    
      The primary objective of this study is to evaluate the efficacy of inhaled nebulized AIR001
      administered, for 16 weeks, according to 3 treatment arms (80 mg once daily, 46 mg 4 times
      daily, or 80 mg 4 times daily) in subjects with World Health Organization (WHO) Group 1
      Pulmonary Arterial Hypertension (PAH), as determined by change in Pulmonary Vascular
      Resistance (PVR) from Baseline to Week 16 measured immediately post completion of AIR001
      nebulization (as soon as feasible).
    
  